TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Patent ExpiryTBS-2025Positive

AI Analysis

Summary

TuHURA Biosciences received a new U.S. patent that broadens coverage of its VISTA inhibitor TBS-2025 to include bispecific and multi-specific antibodies across all human antibody classes, strengthening its intellectual property position for the Phase 3 immuno-oncology program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

U.S. patent broadening coverage to include bispecific/multi-specific antibodies across all classes of human antibodies for VISTA inhibitor

Importance:5/10

Sentiment:

0.60

patentVISTA inhibitorbispecific antibodiesimmuno-oncologyintellectual property

Related Companies

$HURA

Read the original article

Published by PR Newswire Pharma on October 13, 2026 11:45 AM

Read Original